BMRN Class Action: Learn About the BioMarin Lawsuit | Levi & Korsinsky, LLP

[ad_1]

Levi & Korsinsky, LLP announces that a BMRN class action lawsuit has been filed on behalf of investors who purchased BioMarin Pharmaceutical Inc. (BMRN) securities between January 13, 2020, and September 3, 2021 For more on the BMRN Lawsuit please contact us today.

Levi & Kowsinsky Securities Class Action Lawyers

According to the BioMarin lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE BMRN CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in BioMarin you have until December 22, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

[ad_2]

Source link

You may also like...